HRP20201264T1 - Prolijekovi gemcitabina - Google Patents
Prolijekovi gemcitabina Download PDFInfo
- Publication number
- HRP20201264T1 HRP20201264T1 HRP20201264TT HRP20201264T HRP20201264T1 HR P20201264 T1 HRP20201264 T1 HR P20201264T1 HR P20201264T T HRP20201264T T HR P20201264TT HR P20201264 T HRP20201264 T HR P20201264T HR P20201264 T1 HRP20201264 T1 HR P20201264T1
- Authority
- HR
- Croatia
- Prior art keywords
- cancer
- pharmaceutical formulation
- formulation according
- gemcitabine
- alaninyl
- Prior art date
Links
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 title 1
- 229960005277 gemcitabine Drugs 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 229910019142 PO4 Inorganic materials 0.000 claims 5
- 238000009472 formulation Methods 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 239000010452 phosphate Substances 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 229920000858 Cyclodextrin Polymers 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000000728 Thymus Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 239000013011 aqueous formulation Substances 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000003495 polar organic solvent Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 201000009377 thymus cancer Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Claims (11)
1. Farmaceutska formulacija koja sadrži gemcitabin-[fenil-benzoksi-L-alaninil)]-(S)-fosfat 3:
[image]
ili njegovu farmaceutski prihvatljivu sol ili solvat, koji ima diastereoizomernu čistoću veću od 90% i najmanje jedan farmaceutski prihvatljiv ekscipijent; pri čemu je formulacija vodena formulacija koja također sadrži polarno organsko otapalo.
2. Farmaceutska formulacija prema patentnom zahtjevom 1, naznačena time što je formulacija pogodna za parenteralnu primjenu.
3. Farmaceutska formulacija prema patentnom zahtjevu 2, naznačena time što je formulacija pogodna za intravensku primjenu.
4. Farmaceutska formulacija prema bilo kojem od patentnih zahtjeva 1 do 3, naznačena time što formulacija dodatno sadrži ciklodekstrin.
5. Farmaceutska formulacija prema patentnom zahtjevu 1, naznačena time što je formulacija pogodna za oralnu primjenu.
6. Farmaceutska formulacija prema bilo kojem prethodnom patentnom zahtjevu, naznačena time što je gemcitabin-[fenil-benzoksi-L-alaninil)]-(S)-fosfat 3 u obliku slobodne baze.
7. Farmaceutska formulacija prema bilo kojem prethodnom patentnom zahtjevu, naznačena time što gemcitabin-[fenil-benzoksi-L-alaninil)]-(S)-fosfat 3 ima diastereoizomernu čistoću veću od 95%.
8. Farmaceutska formulacija prema patentnom zahtjevu 7, naznačena time što gemcitabin-[fenil-benzoksi-L-alaninil)]-(S)-fosfat 3 ima diastereoizomernu čistoću veću od 98%.
9. Farmaceutska formulacija prema patentnom zahtjevu 8, naznačena time što gemcitabin-[fenil-benzoksi-L-alaninil)]-(S)-fosfat 3 ima diastereoizomernu čistoću veću od 99.5%.
10. Farmaceutska formulacija prema bilo kojem prethodnom patentnom zahtjevu, za uporabu u liječenju raka.
11. Farmaceutska formulacija za uporabu prema patentnom zahtjevu 10, naznačena time što rak je izabran od: raka gušterače, raka dojke, raka jajnika, raka mjehura, kolorektalnog raka, raka pluća, raka mjehura, raka prostate, kolangiokarcinoma, raka bubrega, cervikalnog raka, raka timusa, raka nepoznatog primarnog porijekla, limfoma ili leukemije.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2050MU2014 | 2014-06-25 | ||
| GBGB1411253.6A GB201411253D0 (en) | 2014-06-25 | 2014-06-25 | Prodrug |
| EP15733497.0A EP3160978B1 (en) | 2014-06-25 | 2015-06-25 | Gemcitabine prodrugs |
| PCT/GB2015/051857 WO2015198058A1 (en) | 2014-06-25 | 2015-06-25 | Gemcitabine prodrugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201264T1 true HRP20201264T1 (hr) | 2021-02-05 |
Family
ID=53499027
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230584TT HRP20230584T1 (hr) | 2014-06-25 | 2015-06-25 | Prolijekovi gemcitabina |
| HRP20201264TT HRP20201264T1 (hr) | 2014-06-25 | 2020-08-11 | Prolijekovi gemcitabina |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230584TT HRP20230584T1 (hr) | 2014-06-25 | 2015-06-25 | Prolijekovi gemcitabina |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US10662213B2 (hr) |
| EP (2) | EP3757112B1 (hr) |
| JP (2) | JP6982957B2 (hr) |
| KR (2) | KR102563040B1 (hr) |
| CN (2) | CN106459129B (hr) |
| AU (2) | AU2015278899B2 (hr) |
| CA (1) | CA2945938C (hr) |
| CL (1) | CL2016003260A1 (hr) |
| CY (1) | CY1123389T1 (hr) |
| DK (1) | DK3160978T3 (hr) |
| EA (1) | EA034890B1 (hr) |
| ES (2) | ES2811268T3 (hr) |
| HR (2) | HRP20230584T1 (hr) |
| HU (2) | HUE062474T2 (hr) |
| IL (2) | IL248642B (hr) |
| LT (1) | LT3160978T (hr) |
| ME (1) | ME03817B (hr) |
| MX (2) | MX2021001140A (hr) |
| MY (1) | MY183198A (hr) |
| NZ (2) | NZ725205A (hr) |
| PH (1) | PH12016502553B1 (hr) |
| PL (1) | PL3160978T3 (hr) |
| PT (1) | PT3160978T (hr) |
| RS (1) | RS60968B1 (hr) |
| SG (2) | SG11201608808TA (hr) |
| SI (1) | SI3160978T1 (hr) |
| TW (2) | TWI758728B (hr) |
| WO (1) | WO2015198058A1 (hr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10005810B2 (en) | 2012-11-16 | 2018-06-26 | University College Cardiff Consultants Limited | Process for preparing nucleoside prodrugs |
| LT3160978T (lt) | 2014-06-25 | 2020-08-25 | NuCana plc | Gemcitabino provaistai |
| KR102421929B1 (ko) | 2014-06-25 | 2022-07-15 | 뉴카나 피엘씨 | 젬시타빈-전구 약물 함유 제제 |
| GB201417644D0 (en) | 2014-10-06 | 2014-11-19 | Nucana Biomed Ltd | Method of separating phosphate diastereoisomers |
| CN106543220A (zh) | 2015-09-16 | 2017-03-29 | 博瑞生物医药（苏州）股份有限公司 | 氨基磷酸酯化合物及其制备方法和晶体 |
| CN106539810B (zh) * | 2015-09-16 | 2021-03-09 | 济南高合医疗科技有限公司 | 一种富集了nuc-1031单一异构体的组合物及其制备方法和用途 |
| CN106543252A (zh) * | 2015-09-16 | 2017-03-29 | 博瑞生物医药（苏州）股份有限公司 | 核苷氨基磷酸酯类前药的制备方法及其中间体 |
| CN108135920A (zh) | 2015-10-05 | 2018-06-08 | 努卡那有限公司 | 组合疗法 |
| MX2018007083A (es) | 2015-12-11 | 2019-02-20 | NuCana plc | Sintesis diaestereoselectiva de derivados de fosfato y del profarmaco de gemcitabina nuc-1031. |
| GB201522771D0 (en) | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Crystalline form of a phosphate derivative |
| GB201609600D0 (en) * | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Cancer treatments |
| CN107652342A (zh) * | 2016-07-23 | 2018-02-02 | 江苏万高药业股份有限公司 | 核苷氨基磷酸酯类前药的多晶型及其制备方法 |
| CN106946960A (zh) * | 2017-03-29 | 2017-07-14 | 郑州泰基鸿诺医药股份有限公司 | 一种吉西他滨前药的晶型、制备方法、用途和药物组合物 |
| GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
| CN110806454A (zh) * | 2018-08-06 | 2020-02-18 | 江苏正大清江制药有限公司 | 一种盐酸吉西他滨中手性异构体的检测方法 |
| CN110215469B (zh) * | 2019-07-08 | 2021-11-30 | 绍兴市人民医院 | 一种治疗胆管癌的药物组合物 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5728575A (en) | 1990-02-01 | 1998-03-17 | Emory University | Method of resolution of 1,3-oxathiolane nucleoside enantiomers |
| US6703396B1 (en) | 1990-02-01 | 2004-03-09 | Emory University | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
| PT1045897E (pt) | 1998-01-23 | 2002-07-31 | Newbiotics Inc | Agentes terapeuticos por catalise enzimatica |
| US7462605B2 (en) | 1998-01-23 | 2008-12-09 | Celmed Oncology (Usa), Inc. | Phosphoramidate compounds and methods of use |
| JP4982019B2 (ja) | 1999-07-22 | 2012-07-25 | セルメド オンコロジー （ユーエスエイ）， インコーポレイテッド | 酵素によって触媒される治療活性化 |
| GB0317009D0 (en) * | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| US20080096967A1 (en) | 2005-01-27 | 2008-04-24 | Erimos Pharmaceuticals Llc | Formulations for Injection of Catecholic Butanes, Including Ndga Compounds, Into Animals |
| CA2618335C (en) | 2005-08-15 | 2015-03-31 | F.Hoffmann-La Roche Ag | Antiviral phosphoramidates of 4'-substituted pronucleotides |
| CA2635797C (en) | 2006-02-09 | 2015-03-31 | Macusight, Inc. | Stable formulations, and methods of their preparation and use |
| GB0821994D0 (en) * | 2008-12-02 | 2009-01-07 | Ge Healthcare Ltd | In viva imaging method |
| CN102348712A (zh) | 2009-01-09 | 2012-02-08 | 卡迪夫大学学院顾问有限公司 | 用于治疗病毒感染的鸟苷核苷类化合物的磷酰胺酯衍生物 |
| TWI598358B (zh) | 2009-05-20 | 2017-09-11 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| RU2012125350A (ru) | 2009-11-20 | 2013-12-27 | Клавис Фарма Аса | Парентеральные препараты производных гемцитабина |
| CN103209987B (zh) | 2010-09-22 | 2017-06-06 | 艾丽奥斯生物制药有限公司 | 取代的核苷酸类似物 |
| LT3447061T (lt) | 2011-03-01 | 2022-01-25 | NuCana plc | Farmacinė vaisto forma, apimanti 5-fluor-2'-deoksiuridinofosforamidato darinį, skirtą naudoti vėžio gydymui |
| MX354990B (es) | 2012-01-20 | 2018-03-28 | Aratana Therapeutics Nv | Composicion de gotas para los ojos. |
| US10005810B2 (en) * | 2012-11-16 | 2018-06-26 | University College Cardiff Consultants Limited | Process for preparing nucleoside prodrugs |
| GB2517988A (en) * | 2013-09-09 | 2015-03-11 | Redx Pharma Ltd | Compounds |
| SI3043803T1 (sl) | 2013-09-11 | 2022-09-30 | Emory University | Nukleotidne in nukleozidne sestave in njihova uporaba |
| CN105934438A (zh) * | 2013-11-27 | 2016-09-07 | 艾登尼克斯药业有限公司 | 用于治疗肝癌的核苷酸 |
| KR102421929B1 (ko) | 2014-06-25 | 2022-07-15 | 뉴카나 피엘씨 | 젬시타빈-전구 약물 함유 제제 |
| LT3160978T (lt) | 2014-06-25 | 2020-08-25 | NuCana plc | Gemcitabino provaistai |
| ES2830784T3 (es) | 2014-07-22 | 2021-06-04 | NuCana plc | Proceso para la preparación de gemcitabina-[fenil(benzoxi-L-alanil)]fosfato |
| GB201417644D0 (en) | 2014-10-06 | 2014-11-19 | Nucana Biomed Ltd | Method of separating phosphate diastereoisomers |
| EA201792509A1 (ru) | 2015-05-14 | 2018-05-31 | НУКАНА ПиЭлСи | Лечение рака |
| CN108135920A (zh) | 2015-10-05 | 2018-06-08 | 努卡那有限公司 | 组合疗法 |
| MX2018007083A (es) | 2015-12-11 | 2019-02-20 | NuCana plc | Sintesis diaestereoselectiva de derivados de fosfato y del profarmaco de gemcitabina nuc-1031. |
| CA3008769A1 (en) | 2015-12-23 | 2017-06-29 | NuCana plc | Combination therapy comprising nuc-1031 and cisplatin |
| WO2017109486A1 (en) | 2015-12-23 | 2017-06-29 | Nucana Biomed Limited | Combination therapy |
| GB201522771D0 (en) | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Crystalline form of a phosphate derivative |
-
2015
- 2015-06-25 LT LTEP15733497.0T patent/LT3160978T/lt unknown
- 2015-06-25 KR KR1020227019095A patent/KR102563040B1/ko active IP Right Grant
- 2015-06-25 MX MX2021001140A patent/MX2021001140A/es unknown
- 2015-06-25 HR HRP20230584TT patent/HRP20230584T1/hr unknown
- 2015-06-25 HU HUE20187951A patent/HUE062474T2/hu unknown
- 2015-06-25 TW TW109115415A patent/TWI758728B/zh not_active IP Right Cessation
- 2015-06-25 CA CA2945938A patent/CA2945938C/en active Active
- 2015-06-25 ES ES15733497T patent/ES2811268T3/es active Active
- 2015-06-25 PT PT157334970T patent/PT3160978T/pt unknown
- 2015-06-25 PL PL15733497T patent/PL3160978T3/pl unknown
- 2015-06-25 RS RS20200953A patent/RS60968B1/sr unknown
- 2015-06-25 DK DK15733497.0T patent/DK3160978T3/da active
- 2015-06-25 AU AU2015278899A patent/AU2015278899B2/en active Active
- 2015-06-25 NZ NZ725205A patent/NZ725205A/en unknown
- 2015-06-25 TW TW104120671A patent/TWI695718B/zh not_active IP Right Cessation
- 2015-06-25 ES ES20187951T patent/ES2948660T3/es active Active
- 2015-06-25 SI SI201531314T patent/SI3160978T1/sl unknown
- 2015-06-25 JP JP2016573536A patent/JP6982957B2/ja active Active
- 2015-06-25 EA EA201692312A patent/EA034890B1/ru unknown
- 2015-06-25 HU HUE15733497A patent/HUE053240T2/hu unknown
- 2015-06-25 KR KR1020167033632A patent/KR102407935B1/ko active IP Right Grant
- 2015-06-25 MY MYPI2016002193A patent/MY183198A/en unknown
- 2015-06-25 EP EP20187951.7A patent/EP3757112B1/en active Active
- 2015-06-25 SG SG11201608808TA patent/SG11201608808TA/en unknown
- 2015-06-25 WO PCT/GB2015/051857 patent/WO2015198058A1/en active Application Filing
- 2015-06-25 SG SG10201907898SA patent/SG10201907898SA/en unknown
- 2015-06-25 CN CN201580034740.XA patent/CN106459129B/zh active Active
- 2015-06-25 CN CN202010140546.2A patent/CN111214480A/zh active Pending
- 2015-06-25 NZ NZ765508A patent/NZ765508A/en unknown
- 2015-06-25 ME MEP-2020-171A patent/ME03817B/me unknown
- 2015-06-25 US US15/308,491 patent/US10662213B2/en active Active
- 2015-06-25 EP EP15733497.0A patent/EP3160978B1/en active Active
- 2015-06-25 MX MX2016015628A patent/MX2016015628A/es unknown
-
2016
- 2016-10-31 IL IL248642A patent/IL248642B/en active IP Right Grant
- 2016-12-20 PH PH12016502553A patent/PH12016502553B1/en unknown
- 2016-12-20 CL CL2016003260A patent/CL2016003260A1/es unknown
-
2019
- 2019-08-13 AU AU2019216626A patent/AU2019216626B2/en active Active
-
2020
- 2020-02-17 IL IL272724A patent/IL272724B/en active IP Right Grant
- 2020-04-22 JP JP2020076384A patent/JP6970236B2/ja active Active
- 2020-05-04 US US16/865,527 patent/US11629164B2/en active Active
- 2020-08-10 CY CY20201100745T patent/CY1123389T1/el unknown
- 2020-08-11 HR HRP20201264TT patent/HRP20201264T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201264T1 (hr) | Prolijekovi gemcitabina | |
| MX2022001755A (es) | Compuestos de dinucleotidos ciclicos y metodos de uso. | |
| HRP20191461T1 (hr) | Novi 2' i/ili 5' derivati 3'-deoksi adenozina supstituirani aminokiselinskim esterom fosforamidata, kao antikancerogenog spoja | |
| CY1123627T1 (el) | Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου | |
| PH12016501693A1 (en) | 2,4-disubstituted phenylene-1,5-diamine derivatives and applications thereof, and pharmaceutical compositions and pharmaceutically acceptable compositions prepared therefrom | |
| TN2017000511A1 (en) | New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them. | |
| MX2017008518A (es) | Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih). | |
| PH12017501539A1 (en) | Disacetoxytubulysin h and analogs thereof | |
| PH12019501178A1 (en) | Thiopene derivatives as antiviral agents | |
| ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
| HRP20201681T1 (hr) | Inhibitor aurora a kinaze | |
| CY1124580T1 (el) | Φαρμακευτικα σκευασματα που περιλαμβανουν παραγωγα φαινυλαμινοπυριμιδινης | |
| WO2016001905A3 (en) | Stable liquid ready-to-use injectable formulation of bortezomib | |
| PH12017502046A1 (en) | Salts and prodrugs of 1-methyl-d-tryptophan | |
| HK1248544A1 (zh) | 穩定的口服給藥用藥物組合物 | |
| HK1255345A1 (zh) | 含有高濃度紫杉烷的用於口服給藥的藥物組合物 | |
| MX2017002544A (es) | Derivados de isoquinolinona utiles en el tratamiento contra el cancer. | |
| IL261929B (en) | Stable pharmaceutical preparations for topical administration and their use | |
| CO2017004382A2 (es) | Composiciones farmacéuticas que comprenden lobeglitazona para administración oral | |
| MX2017002627A (es) | Derivados de polieteres macrociclicos de n-aril-2-amino-4-aril-pir imidina como inhibidores de ftl3 y jak. | |
| CL2017000026A1 (es) | Formas de dosificación farmacéutica | |
| MX2017002747A (es) | Derivados de polieteres macrociclicos de n-aril-triciclopirimidin- 2-amino como inhibidores de ftl3 y jak. | |
| IL262489A (en) | Complexes of ivacaptor and its salts and their history, a process for their preparation and pharmaceutical preparations containing them | |
| IL262490A (en) | Lomacaptor complexes and their salts and derivatives, a process for their preparation and pharmaceutical preparations containing them | |
| UA109242U (uk) | Стабільна фармацевтична композиція, що містить інгібітор протеасом |